الفهرس 
EpilepsyOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
This study was conducted in 4 weeks duration on 44 children and adolescents with idiopathic epilepsy treated with VPA monotherapy divided into two groups each group included 22 patients. Group A (Intervention /Control- I/C) included 22 patients who received a calculated daily dose of honey 1.2gm/kg/day for 2 weeks (Intervention-I) to explore the effect of its intake on GPx serum levels, followed by another 2 weeks without receiving honey (Control-C) to explore the effect of its stoppage. Group B (Control/Intervention- C/I) included 22 patients who did not receive honey for the 1st 2 weeks of the study (control-C) to examine whether the change was due to honey ingestion later or not, followed by another 2 weeks in which they received honey as in the protocol of group A to further elucidate the effect of Honey intake on them too. The patients were recruited from the regular attendants of the children in the out-patients neurological pediatric clinic of Ain Shams university hospital.
All patients were subjected to: 1) Full history taking including seizure type, seizures’ frequency/2 weeks, history of sodium valproate therapy. 2) Data from each patient’s file was accurately recorded as regards the epilepsy type according to the international classification of the International League against Epilepsy (ILAE), duration of disease and duration since last seizure. 3) Honey was given in a daily oral dose of 1.2 g/kg for 2 weeks according to the protocol of each group. 4) Thorough clinical examination. 5) Follow up procedures were performed at enrollment, 2weeks and 4 weeks of the study including, seizures’ frequency/2weeks, alanine amino-transferase (ALT) serum level measurement and serum level of Glutathione peroxidase by colormetric method
And we found that:
Our study included 44 patients (23male, 21 female) with idiopathic epilepsy 23 had generalized seizures type and 21 had focal ones. They were divided into 2 groups, the Intervention group-I/C (group I) and the Control group-C/I (group II).
On comparing baseline studied variables between them, there were no statistical significant differences as regard baseline characteristics of patients except in age of patients, duration of disease/monthes and in duration of VPA intake/monthes. As there were a statistical significant longer duration of disease and VPA intake/monthes in group II compared to group I.
There were a significant difference as regard GPx serum levels in the intervention period between group I(0-2wks)and group II(2-4wks), as there were a lower significant increase in the mean values of GPx serum levels in group II compared to group I.
There were a significant difference as regard GPx serum level in the control period between group I (2-4wks) and group II (0-2wks), as there were a lower significant reduction in the mean values of GPx serum levels in group I compared to group II.
In group I, the difference in the rate of change as regard seizure frequency shows a significant reduction in the intervention period (0-2wks) compared to control period (2-4wks). Meanwhile, there was no statistical significant change as regard ALT serum during both the study periods in the same group.
Moreover, There were statistical highly significant increase in the rate of change in mean values of GpX serum (nmol/min/ml) levels among group I in the intervention period (0-2wks), but there were statistical significant reduction in the rate of changes in mean values of GpX serum levels among the group in the control period (2-4wks) when compared to the intervention period.
In group II, the difference in the rate of change as regard seizure frequency shows a significant reduction in the intervention period (2-4wks) when compared to the control period (0-2wks). Meanwhile, there were statistical significant increase change as regard ALT serum in both study periods.
Moreover, There were statistical non significant rate of change of mean values of GpX serum (nmol / min./ml) levels among group II in control period (0-2wks), but there were statistically highly significant increase in the rate of change in mean values of GpX levels among the group in the intervention period.
There was a significant negative correlation between baseline serum levels of GPx and ALT. However, there was no other significant correlations with the other parameters.